Vident Investment Advisory, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Vident Investment Advisory, LLC

$0
Q3 2023

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$185.01 - $212.05 $211,651 - $242,585	1,144 New	1,144 $217,000
Q2 2022 Aug 15, 2022	SELL	$120.42 - $169.29 $1.46 Million - $2.06 Million	-12,161 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $653,196 - $893,201	5,136 Added 73.11%	12,161 $1.98 Million
Q4 2021 Feb 14, 2022	SELL	$159.56 - $209.29 $678,927 - $890,528	-4,255 Reduced 37.72%	7,025 $1.19 Million
Q3 2021 Nov 12, 2021	BUY	$169.75 - $207.73 $150,907 - $184,671	889 Added 8.56%	11,280 $2.13 Million
Q2 2021 Aug 13, 2021	SELL	$128.63 - $176.89 $155,127 - $213,329	-1,206 Reduced 10.4%	10,391 $1.76 Million
Q1 2021 May 14, 2021	BUY	$126.83 - $175.69 $82,566 - $114,374	651 Added 5.95%	11,597 $1.64 Million
Q4 2020 Feb 08, 2021	BUY	$122.97 - $147.0 $107,352 - $128,331	873 Added 8.67%	10,946 $1.42 Million
Q3 2020 Nov 12, 2020	SELL	$121.19 - $165.49 $35,023 - $47,826	-289 Reduced 2.79%	10,073 $1.47 Million
Q2 2020 Jul 17, 2020	BUY	$104.21 - $156.44 $792,308 - $1.19 Million	7,603 Added 275.57%	10,362 $1.53 Million
Q1 2020 May 12, 2020	BUY	$93.12 - $133.99 $34,081 - $49,040	366 Added 15.29%	2,759 $300,000
Q4 2019 Feb 11, 2020	SELL	$74.51 - $124.23 $130,839 - $218,147	-1,756 Reduced 42.32%	2,393 $276,000
Q3 2019 Nov 13, 2019	SELL	$70.9 - $87.82 $93,658 - $116,010	-1,321 Reduced 24.15%	4,149 $334,000
Q2 2019 Aug 12, 2019	SELL	$65.86 - $92.79 $225,372 - $317,527	-3,422 Reduced 38.48%	5,470 $397,000
Q1 2019 May 08, 2019	BUY	$72.76 - $93.45 $111,177 - $142,791	1,528 Added 20.75%	8,892 $831,000
Q4 2018 Feb 14, 2019	SELL	$62.67 - $88.33 $10,653 - $15,016	-170 Reduced 2.26%	7,364 $537,000
Q3 2018 Nov 14, 2018	SELL	$87.52 - $122.67 $7,789 - $10,917	-89 Reduced 1.17%	7,534 $659,000
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $278,794 - $340,324	3,157 Added 70.69%	7,623 $751,000
Q1 2018 May 14, 2018	BUY	$115.92 - $148.54 $278,208 - $356,496	2,400 Added 116.17%	4,466 $429,000
Q4 2017 Feb 15, 2018	BUY	$114.49 - $139.98 $236,536 - $289,198	2,066	2,066 $262,000

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

Capital World Investors Los Angeles, CA

16.5M
Shares

$4.19 Billion
0.73% of portfolio
Vanguard Group Inc Valley Forge, PA

12.6M
Shares

$3.21 Billion
0.06% of portfolio
Black Rock Inc. New York, NY

9.55M
Shares

$2.42 Billion
0.05% of portfolio
Capital Research Global Investors Los Angeles, CA

5.24M
Shares

$1.33 Billion
0.31% of portfolio
Wellington Management Group LLP Boston, MA

4.95M
Shares

$1.26 Billion
0.24% of portfolio

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Investment Advisory, LLC with notifications on news.

Account